Patents Assigned to SANTARUS, INC
-
Publication number: 20220133778Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.Type: ApplicationFiled: September 30, 2021Publication date: May 5, 2022Applicant: Santarus, Inc.Inventors: Kay Olmstead, Warren Hall, Gerald T. Proehl
-
Publication number: 20200163888Abstract: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.Type: ApplicationFiled: August 6, 2019Publication date: May 28, 2020Applicants: COSMO TECHNOLOGIES LIMITED, SANTARUS, INC.Inventors: Gerald Thomas PROEHL, Wendell WIERENGA, Michael Fangching HUANG, Emerson David BALLARD, II, Luigi MORO
-
Patent number: 10555907Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.Type: GrantFiled: August 31, 2018Date of Patent: February 11, 2020Assignee: Santarus, Inc.Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
-
Publication number: 20190231699Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.Type: ApplicationFiled: August 31, 2018Publication date: August 1, 2019Applicant: Santarus, Inc.Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
-
Patent number: 10316095Abstract: Formulations of anti-VLA-1 antibodies are described.Type: GrantFiled: February 14, 2013Date of Patent: June 11, 2019Assignee: Santarus, Inc.Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
-
Publication number: 20190022131Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.Type: ApplicationFiled: September 21, 2018Publication date: January 24, 2019Applicant: Santarus, Inc.Inventors: Kay Olmstead, Warren Hall, Gerald T. Proehl
-
Patent number: 10160808Abstract: Formulations of anti-VLA-1 antibodies are described.Type: GrantFiled: February 14, 2013Date of Patent: December 25, 2018Assignee: Santarus, Inc.Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
-
Patent number: 10071058Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.Type: GrantFiled: March 6, 2013Date of Patent: September 11, 2018Assignee: Santarus, Inc.Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
-
Publication number: 20160361394Abstract: A method for treating acute attacks of hereditary angioedema (HAE) whereby a first does and a second dose of a recombinant C1 esterase inhibitor is administered intravenously to the patient, each dose at 50 IU/kg body weight of the patient and wherein the first and second doses are administered within a 24 hour period. The recombinant C1 esterase inhibitor has an amino acid sequence identical to the amino acid sequence of human plasma-derived C1 esterase inhibitor and a modified carbohydrate structure as compared to the human plasma-derived C1 esterase inhibitor. Relief of attack symptoms as well as reduction of relapse and/or new attack symptoms are achieved by use of the method.Type: ApplicationFiled: February 27, 2015Publication date: December 15, 2016Applicant: Santarus, Inc.Inventor: Mark C. Totoritis
-
Publication number: 20150202226Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.Type: ApplicationFiled: March 30, 2015Publication date: July 23, 2015Applicant: SANTARUS, INC.Inventors: Warren Hall, Kay Olmstead, Laura Weston
-
Patent number: 8993599Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.Type: GrantFiled: January 24, 2006Date of Patent: March 31, 2015Assignee: Santarus, Inc.Inventors: Warren Hall, Kay Olmstead, Laura Weston
-
Publication number: 20150056275Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.Type: ApplicationFiled: March 6, 2013Publication date: February 26, 2015Applicant: SANTARUS, INC.Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
-
Publication number: 20150017239Abstract: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.Type: ApplicationFiled: February 13, 2013Publication date: January 15, 2015Applicants: SANTARUS INC., COSMO TECHNOLOGIES LIMITEDInventors: Luigi Moro, Gerald Thomas Proehl, Wendell Wierenga, Michael Fangching Huang, Emerson David Ballard, II
-
Publication number: 20140370104Abstract: Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at least one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump inhibitor and at least one antacid.Type: ApplicationFiled: February 14, 2014Publication date: December 18, 2014Applicant: Santarus, Inc.Inventors: Warren HALL, Kay OLMSTEAD, Laura WESTON
-
Patent number: 8906940Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.Type: GrantFiled: May 25, 2005Date of Patent: December 9, 2014Assignee: Santarus, Inc.Inventors: Kay Olmstead, Warren Hall, Gerald T. Proehl
-
Publication number: 20140271853Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: SANTARUS, INC.Inventors: Warren Hall, Laura Weston, Kay Olmstead, Laura Gallo, Craig Bowe
-
Patent number: 8815916Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.Type: GrantFiled: November 28, 2005Date of Patent: August 26, 2014Assignee: Santarus, Inc.Inventors: Kay Olmstead, Warren Hall, Gerald T. Proehl
-
Publication number: 20140187517Abstract: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Applicants: SANTARUS, INC., COSMO TECHNOLOGIES LIMITEDInventors: Gerald Thomas PROEHL, Wendell WIERENGA, Michael Fangching HUANG, Emerson David BALLARD, II, Luigi MORO
-
Publication number: 20140010827Abstract: Formulations of anti-VLA-1 antibodies are described.Type: ApplicationFiled: August 30, 2013Publication date: January 9, 2014Applicant: SANTARUS, INC.Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
-
Publication number: 20130225537Abstract: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.Type: ApplicationFiled: April 5, 2013Publication date: August 29, 2013Applicants: SANTARUS, INC., COSMO TECHNOLOGIES LIMITEDInventors: Cosmo Technologies Limited, Santarus, Inc.